P/E ratio for Innoviva (INVA)
P/E ratio as of April 2024 (TTM): 18.1
According to Innoviva's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 18.1358. At the end of 2022 the company had a P/E ratio of 4.32.
P/E ratio history for Innoviva from 2005 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 4.32 | -21.69% |
| 2021 | 5.51 | -1.25% |
| 2020 | 5.58 | -39.3% |
| 2019 | 9.19 | 106.03% |
| 2018 | 4.46 | -60.37% |
| 2017 | 11.3 | -42.11% |
| 2016 | 19.5 | -129.53% |
| 2015 | -65.9 | 602.98% |
| 2014 | -9.37 | -45.52% |
| 2013 | -17.2 | -88.48% |
| 2012 | -149 | 1082.44% |
| 2011 | -12.6 | -26.85% |
| 2010 | -17.3 | 122.96% |
| 2009 | -7.74 | 18.67% |
| 2008 | -6.53 | 9.63% |
| 2007 | -5.95 | -32.57% |
| 2006 | -8.83 | 30.84% |
| 2005 | -6.75 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 OPKO Health
OPK | -4.56 | -125.12% | 🇺🇸 USA |
 Onconova Therapeutics ONTX | -0.9953 | -105.49% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.